Jump to content

Incyte

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 09:19, 17 January 2021 (Task 18 (cosmetic): eval 16 templates: hyphenate params (5×); del |url-status= (1×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Incyte Corporation
Company typePublic
Nasdaq: INCY
NASDAQ-100 Component
S&P 500 Component
Industrypharmaceutical company
Founded1991 (1991)
Headquarters
Wilmington, Delaware
,
United States
Key people
Hervé Hoppenot (President and CEO, 2014)
RevenueIncrease $US 1.5 billion (2017)
Decrease $US (313) million (2017)
Total assetsIncrease $US 1.504 billion (2017)
Total equityIncrease $US 1.632 billion (2017)
Number of employees
1,456[1] (2020)
Websitewww.incyte.com
Footnotes / references
[2]

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.[3] The company was founded in Palo Alto, California in 1991 and went public in 1993.[4]

Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to patients in the United States.[3]

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[5][6] It gained EU approval in February 2017.[7] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[8][9]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[10][11]

In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060).[12]

History

In 2014, Incyte named Hervé Hoppenot president and CEO.[13] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[13]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[14]

In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[15] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[16]

References

  1. ^ "Incyte". Fortune 500. Fortune Media IP Limited. 18 May 2020. Company information. Retrieved 19 December 2020.
  2. ^ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, archived from the original on January 26, 2013, retrieved May 6, 2012
  3. ^ a b Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
  4. ^ Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
  5. ^ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Archived from the original on 8 March 2015. Retrieved 2 Mar 2015.
  6. ^ "Baricitinib" (pdf). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  7. ^ "Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.
  8. ^ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  9. ^ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  10. ^ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European journal of cancer (Oxford, England : 1990). 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
  11. ^ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
  12. ^ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
  13. ^ a b "People". Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 41.
  14. ^ "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
  15. ^ "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
  16. ^ "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
  • Business data for Incyte:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Incyte&oldid=1000908624"